ClinicalTrials.gg
RecruitingNCT07363018RIFUpdated Nov 12, 2026

Efficacy of a Non-Invasive Endometrial Receptivity Prediction Model Based on Peripheral Blood miRNA Signatures During the Peri-Implantation Period in Improving IVF Outcomes in Patients With Unexplained RIF

An interventional study of Non-invasive endometrial receptivity prediction model guides personalized embryo transfer for patients with recurrent implantation failure (RIF). in Recurrent Implantation Failure, sponsored by Tang-Du Hospital. Recruiting at 1 site in China. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Tang-Du Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 12, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
546
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Female
01

Study summary

The goal of this clinical trial aims to investigate whether a non-invasive implantation window prediction model, constructed based on characteristic changes in peripheral blood miRNAs during the peri-implantation period, can improve pregnancy outcomes in patients with unexplained recurrent implantation failure undergoing frozen embryo transfer. Researchers will compare the clinical pregnancy outcomes between individualized embryo transfer guided by implantation window results and conventional embryo transfer, to observe whether implantation window-guided individualized embryo transfer can improve the clinical efficacy for patients with recurrent implantation failure (RIF). Participants will complete implantation window testing as required by the study protocol, undergo randomization and blinding, and proceed with embryo transfer according to their assigned group.

02

Conditions studied

  • Recurrent Implantation Failure
03

In context

Lead sponsor

Tang-Du Hospital is the lead sponsor of 167 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
20 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with unexplained recurrent implantation failure (RIF) meeting the diagnostic criteria for RIF: adult women under 40 years old who have failed to achieve clinical pregnancy after 3 embryo transfer cycles; or after transferring at least 3 high-quality embryos.

    Definition of high-quality embryos: Day 3 embryos (with a cell count ≥7 and fragmentation rate \<10%) and blastocysts (≥3BB).

  2. Endometrial thickness ≥7 mm during the embryo transfer cycle.
  3. Women planning to undergo frozen-thawed embryo transfer (FET) following in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
  4. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Known causes of embryo implantation failure, such as infections, reproductive tract malformations, uterine cavity factors, adenomyosis or endometriosis, system diseases (diagnosed by immunology department), hydrosalpinx, etc.
  2. Couples with chromosomal abnormalities (excluding chromosomal polymorphisms) or familial genetic disorders in either or both partners.
  3. Women with a history of recurrent miscarriage.
  4. Women with to pregnancy or assisted reproductive technology.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
546 participants (estimated)

Study arms

  • Experimental
    Individualized Embryo Transfer Group

    Diagnostic Test: Non-invasive endometrial receptivity prediction model guides personalized embryo transfer for patients with recurrent implantation failure (RIF).

  • No intervention
    Standard Embryo Transfer Group

Interventions

  • Diagnostic testNon-invasive endometrial receptivity prediction model guides personalized embryo transfer for patients with recurrent implantation failure (RIF).

    Participants will undergo personalized embryo transfer based on the detection results of the window of implantation (WOI) via peripheral blood miRNA analysis. For subjects whose WOI results indicate that Day 5 (D5) is non-receptive, the embryo transfer timing will be appropriately advanced or delayed by 24 or 48 hours relative to the standard time. For subjects whose WOI results indicate that D5 is receptive, embryo transfer will be performed at the standard time (the fifth day after ovulation).

06

What researchers measure

Primary outcomes

  1. Implantation rate per embryo transferred, assessed by counting gestational sacs on ultrasound.

    Implantation rate is defined as the number of gestational sacs observed on ultrasound divided by the total number of embryos transferred. It will be expressed as a percentage: (Total number of gestational sacs / Total number of embryos transferred) × 100%. Assessment will occur approximately 35 days after embryo transfer.

    Time frame: From the day of embryo transfer until the completion of the first ultrasound assessment (typically at 35 days ± 7 days after transfer).

Secondary outcomes

  1. Proportion of patients with abnormal endometrial receptivity, as assessed by dynamic changes in peripheral blood microRNA levels 5 days after ovulation.

    Endometrial receptivity will be assessed via the dynamic changes in specific microRNA expression profiles in peripheral blood, measured 5 days after ovulation (day of trigger). The "abnormal receptivity" (non-receptive) status is defined as a microRNA profile falling outside the established reference range for the receptive phase. The proportion will be calculated as: (Number of patients with a non-receptive microRNA profile / Total number of patients measured) × 100%.

    Time frame: From the day of ovulation trigger until the completion of microRNA sample collection and analysis (within 5 to 7 days post-trigger).

  2. Clinical pregnancy rate per embryo transfer, confirmed by ultrasound visualization of gestational sac and fetal heartbeat.

    Clinical pregnancy is defined as the presence of at least one intrauterine gestational sac with detectable fetal cardiac activity on transvaginal ultrasound. The rate will be calculated as: (Number of cycles achieving clinical pregnancy / Number of cycles with embryo transfer) × 100%.

    Time frame: From the day of embryo transfer until the confirmation of clinical pregnancy by ultrasound (assessed at approximately 35 days ± 7 days after embryo transfer).

  3. Ongoing Pregnancy Rate per embryo transfer, confirmed by ultrasound after 12 weeks of gestation.

    Ongoing pregnancy is defined as an intrauterine pregnancy with confirmed fetal viability beyond 12 weeks of gestation (i.e., after the first trimester). The rate will be calculated as the number of cycles achieving an ongoing pregnancy divided by the number of cycles with embryo transfer, expressed as a percentage: (Number of ongoing pregnancies / Number of embryo transfer cycles) × 100%. Fetal viability will be assessed via transvaginal or abdominal ultrasound, demonstrating the presence of fetal cardiac activity.

    Time frame: From the day of embryo transfer until the confirmation of fetal viability at or after 12 weeks of gestation (typically up to 14 weeks of gestation).

07

Study locations

1 of 1 sites recruiting
  • Department of Obstetrics and Gynecology, Reproductive Medicine Center, Tangdu Hospital, Air Force Medical University
    Xi'an, Shannxi 710038, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Sep 2027, 18 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2025
First posted
Jan 23, 2026
StartActual
Mar 23, 2026was Feb 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
1 site added — first site in China
Show site
  • Department of Obstetrics and Gynecology, Reproductive Medicine Center, Tangdu Hospital, Air Force Medical University · Xi'an, China
Nov 12, 2026
Start date
Feb 2026→Mar 23, 2026 (actual)
Nov 12, 2026
Eligibility
1 inclusion criterion edited, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedFemale BMI: 18.5-25 kg/m².
  • EditedWomen planning to undergo frozen-thawed embryo transfer (FET) of blastocysts following in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Department of Obstetrics and Gynecology, Reproductive Medicine Center, Tangdu Hospital, Air Force Medical University · Xi'an, China
    Start date Feb 2026→Mar 23, 2026 (now actual)
    Eligibility 1 inclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedFemale BMI: 18.5-25 kg/m².
    • EditedWomen planning to undergo frozen-thawed embryo transfer (FET) of blastocysts following in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07363018
Lead sponsor
Tang-Du Hospital
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Mar 23, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion